Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension of Treprostinil Palmitil Inhalation Powder in Pulmonary Arterial Hypertension
jRCT2061220089Active, not recruiting
- Sponsor
- Insmed Incorporated
- Start
- Mar 2023
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
01
Overview
Open-label trial of treprostinil palmitil in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Insmed Incorporated. Primary endpoint: Treatment-emergent adverse events. Started Mar 2023; status: active, not recruiting.
02
Drugs
treprostinil palmitil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on jRCT2061220089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061220089.